BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 10461057)

  • 1. Dose intensification of platinum compounds with glutathione protection as induction chemotherapy for advanced ovarian carcinoma.
    Böhm S; Oriana S; Spatti G; Di Re F; Breasciani G; Pirovano C; Grosso I; Martini C; Caraceni A; Pilotti S; Zunino F
    Oncology; 1999; 57(2):115-20. PubMed ID: 10461057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose cisplatin and cyclophosphamide with glutathione in the treatment of advanced ovarian cancer.
    Di Re F; Bohm S; Oriana S; Spatti GB; Pirovano C; Tedeschi M; Zunino F
    Ann Oncol; 1993 Jan; 4(1):55-61. PubMed ID: 8435364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-intensity intravenous cyclophosphamide and cisplatin, interim surgical debulking, and intraperitoneal cisplatin in advanced ovarian carcinoma: a pilot trial with ten-year follow-up.
    Shapiro F; Schneider J; Markman M; Reichman BS; Venkatraman E; Barakat R; Almadrones L; Spriggs D
    Gynecol Oncol; 1997 Oct; 67(1):39-45. PubMed ID: 9345354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer.
    van der Burg ME; Onstenk W; Boere IA; Look M; Ottevanger PB; de Gooyer D; Kerkhofs LG; Valster FA; Ruit JB; van Reisen AG; Goey SH; van der Torren AM; ten Bokkel Huinink D; Kok TC; Verweij J; van Doorn HC
    Eur J Cancer; 2014 Oct; 50(15):2592-601. PubMed ID: 25096168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
    Thigpen T; Vance R; Puneky L; Khansur T
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose platinum versus standard dose in advanced ovarian carcinoma: a randomized trial from the Gynecologic Cooperative Group of the French Comprehensive Cancer Centers (FNCLCC).
    Joly F; Héron JF; Kerbrat P; Chauvergne J; Rios M; Mayer F; Chinet-Charrot P; Goupil A; Lebrun-Jezekova D; Vennin D; Lhommé C; Macé-Lesec'h J; Crouet H
    Gynecol Oncol; 2000 Sep; 78(3 Pt 1):361-8. PubMed ID: 10985895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of high-dose cisplatin and cyclophosphamide with glutathione protection in the treatment of bulky advanced epithelial ovarian cancer.
    Di Re F; Bohm S; Oriana S; Spatti GB; Zunino F
    Cancer Chemother Pharmacol; 1990; 25(5):355-60. PubMed ID: 2306797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carboplatin/cyclophosphamide combination chemotherapy for advanced ovarian cancer.
    Teeling M; Hayes Y; Fitzmaurice B; McGing P; Carney DN
    Semin Oncol; 1992 Feb; 19(1 Suppl 2):102-6. PubMed ID: 1411620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy of advanced ovarian cancer.
    Martoni A; Cacciari N; Angelelli B; Zamagni C; Pannuti F
    Front Biosci; 1997 Mar; 2():g20-6. PubMed ID: 9159262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cisplatin, carboplatin, and cyclophosphamide combination chemotherapy in advanced-stage ovarian carcinoma: an Eastern Cooperative Oncology Group pilot study.
    Grem J; O'Dwyer P; Elson P; Simon N; Trump D; Frontiera M; Falkson G; Vogl S
    J Clin Oncol; 1991 Oct; 9(10):1793-800. PubMed ID: 1919629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose cisplatin carboplatin chemotherapy in primary advanced epithelial ovarian cancer.
    Fanning J; Hilgers RD
    Gynecol Oncol; 1993 Nov; 51(2):182-6. PubMed ID: 8276291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
    Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma.
    Gershenson DM; Morris M; Burke TW; Levenback C; Wolf J; Lee JJ; Thall PF; Atkinson EN; Silva EG; Wharton JT
    Cancer; 1999 Dec; 86(11):2291-300. PubMed ID: 10590370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.
    Skarlos DV; Aravantinos G; Kosmidis P; Athanassiadis A; Stathopoulos GP; Pavlidis N; Bafaloukos D; Karphathios S; Papakostas P; Bamia C; Fountzilas G
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-57-S15-61. PubMed ID: 9346224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of impact of platinum dose intensity on the outcome of ovarian cancer patients. 10-year results of a prospective randomised phase III study comparing carboplatin-cisplatin with cyclophosphamide-cisplatin.
    Dittrich Ch; Sevelda P; Salzer H; Obermair A; Speiser P; Breitenecker G; Schemper M; Kaider A;
    Eur J Cancer; 2003 May; 39(8):1129-40. PubMed ID: 12736113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second-line chemotherapy with cisplatin-ifosfamide in patients with ovarian cancer previously treated with carboplatin-cyclophosphamide.
    Polyzos A; Tsavaris N; Kosmas C; Petrikos G; Giannikos L; Kalahanis N; Papadopoulos O; Christodoulou K; Giannakopoulos K; Veslemes M; Katsilambros N
    J Chemother; 1999 Apr; 11(2):144-9. PubMed ID: 10326746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined carboplatin and cisplatin. Limited prospects for dose intensification.
    Waterhouse DM; Reynolds RK; Natale RB
    Cancer; 1993 Jun; 71(12):4060-6. PubMed ID: 8508371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical study of topotecan and cisplatin as first line chemotherapy in epithelial ovarian cancer].
    Meng LH; Kong BH; Zhang YZ; Yang XS; Wang LJ; Su SL; Jiang J; Cui BX; Wang B
    Zhonghua Fu Chan Ke Za Zhi; 2007 Oct; 42(10):683-7. PubMed ID: 18241544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
    Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
    Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined cisplatin and carboplatin chemotherapy for treatment of advanced epithelial ovarian cancer.
    Gershenson DM; Morris M; Burke TW; Levenback C; Kavanagh JJ; Fromm GL; Silva EG; Warner D; Wharton JT
    Gynecol Oncol; 1995 Sep; 58(3):349-55. PubMed ID: 7672700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.